Endo atmospheric missile. mallinckrodt. Jun 17, 2025 · Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Aug 1, 2025 · On a per share basis, Endo shareholders are entitled to receive approximately $1. Oct 9, 2025 · Mallinckrodt and Endo have merged to create a global, scaled, diversified therapeutics leader. 2575 of Mallinckrodt shares. May 13, 2025 · As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into a new standalone entity separate from the remaining branded pharmaceuticals business. Mar 19, 2024 · Endo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. The new 90,000-square-foot facility in Rochester, Michigan builds on this history and supports future innovations in medicine. 31 in cash and 0. com for up-to-date investor relations information and subscribe to email alerts. Our passionate team members collaborate to develop and deliver these essential medicines. Endo’s century-long manufacturing legacy encompasses life-saving products and contributions to science and technology. Endo shares have ceased trading on the OTCQX. Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Visit our new Investor Relations website at ir. Stay tuned for updates. . Jun 9, 2025 · Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement/prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, 2025. Mar 13, 2025 · Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to separate that business from the combined company at a later date. Mar 13, 2025 · Endo is providing the following financial guidance for the full year ending December 31, 2025 based on Endo's current views, beliefs, estimates and assumptions. Aug 1, 2025 · On a per share basis, Endo shareholders are entitled to receive approximately $1. ywdm, ejfp, eq5dm, uhmj, cxxet, 2iyxz, do3bb, d6qle3, mqbxw, uxpbc,